Latest db-oto results demonstrate clinically meaningful hearing improvements in nearly all children with profound genetic hearing loss in chord trial

As presented at aro, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing speech and development progress followed dramatic improvements in hearing in first child treated in the trial tarrytown, n.y., feb. 24, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced updated data for the investigational gene therapy db-oto from the phase 1/2 chord trial in 12 children who have profound genetic hearing loss due to variants of the otoferlin (otof) gene.
REGN Ratings Summary
REGN Quant Ranking